Nakagawa, Takahiko http://orcid.org/0000-0002-0127-1529
Lanaspa, Miguel A.
Millan, Inigo San
Fini, Mehdi
Rivard, Christopher J.
Sanchez-Lozada, Laura G.
Andres-Hernando, Ana
Tolan, Dean R.
Johnson, Richard J.
Funding for this research was provided by:
National Institutes of Health (NIDDK 1RO1DK108408-01A1, U01AA027997, R01 DK108859-01)
Article History
Received: 10 March 2020
Accepted: 1 July 2020
First Online: 10 July 2020
Ethics approval and consent to participate
: Not applicable
: Not applicable
: MAL, DRT, LGL, CJR, and RJJ have equity in a start-up company developing fructokinase inhibitors (Colorado Research Partners LLC), and TN and RJJ also have equity with XORTX therapeutics which is developing novel xanthine oxidase inhibitors. All others declare no conflicts of interest.